Endocrine Abstracts

Background and AimsPeople with type 1 diabetes (T1D) have an increased risk of cardiovascular disease (CVD) despite insulin therapy to treat hyperglycaemia. Insulin resistance may be a contributing factor to CVD. Insulin resistance is strongly associated with NAFLD, which is increasingly linked to CVD. The estimated glucose disposal rate (eGDR) correlates well with the euglycemic clamp, which is the gold standard to assess insulin resistance in T1D, but ...

Background and aims: Insulin resistance is increasingly prevalent in patients with type 1 diabetes (T1D). Insulin resistance is associated with both cardiovascular complications and non-alcoholic fatty liver disease (NAFLD), but its assessment is challenging in T1D due to the technical difficulties of the euglycaemic clamp technique. The estimated glucose disposal rate (eGDR) is a validated alternative to quantify insulin resistance in T1D, but its role in clinical practice is...

Introduction: The prevalence of metabolic syndrome is increasing in individuals with T1D, which could potentiate the development of NAFLD. The pathophysiology of NAFLD in T1D is still unclear, due to the co-existence of predisposing and protective factors. Insulin resistance (IR) is theorized as a key driver of NAFLD.Aim: We investigated the association between liver fat content (LFC), NAFLD, and IR in individuals with T1D. Subjects underwent magnetic re...

Background: Insulin resistance is proposed as a causative factor of non-alcoholic fatty liver disease (NAFLD) in the general population. Reports on NAFLD in type 1 diabetes (T1D) are increasing , but whether insulin resistance is linked to NAFLD in this population needs elucidation. Furthermore, people with T1D are an excellent model to investigate insulin resistance in relation to NAFLD without confounding by autologous insulin production.Aims and Metho...

Introduction: Nonalcoholic fatty liver disease (NAFLD) affects ±55% of subjects with type 2 diabetes and contributes to cardiovascular mortality. NAFLD data in type 1 diabetes (T1DM) are scarce. Biopsy is the diagnostic reference but is not suited for routine screening. Ultrasound (US) is validated to diagnose steatosis as first-line imaging but is restricted to trained operators. The Fatty Liver Index (FLI) is a score to predict fatty liver based on triglycerides, Body M...

IntroductionLipid accumulation product (LAP), an index based on waist circumference (WC) and serum triglyceride levels, is associated with the presence and severity of non-alcoholic fatty liver disease (NAFLD). However, its potential as a risk marker of NAFLD in subjects with type 1 diabetes (T1D) has not been studied yet.AimsThis study evaluated the ability of LAP to estimate the presence of NAFLD in adults ...

Background and aimsLow levels of testosterone and non-alcoholic fatty liver disease (NAFLD) in obese men are both linked to the metabolic syndrome, but the independent association between testosterone and NAFLD needs to be elucidated. In this cross-sectional analysis the association between total testosterone (total T) and calculated free testosterone (cFT) on the one hand and NAFLD, non-alcoholic steatohepatitis (NASH) and fibrosis on the other hand was...

Background: Patients with type 1 diabetes (T1D) have an increased risk of cardiovascular disease (CVD), despite insulin therapy. Insulin resistance is strongly associated with non-alcoholic fatty liver disease (NAFLD) and CVD. The euglycemic clamp, the gold standard to assess insulin resistance in T1D, is unsuited for clinical practice. The estimated glucose disposal rate (eGDR) is increasingly used as an alternative in T1D, but its role as a NAFLD or CVD predictor is unexplor...

Introduction: Dysregulation of glucocorticoid (GC) metabolism is implicated in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). The only available treatment for NAFLD is weight loss and the gold standard diagnostic test is liver biopsy, which is invasive and resource intensive. NAFLD ranges from simple steatosis, to inflammation (steatohepatitis/NASH), fibrosis and cirrhosis. It may be regarded as the hepatic manifestation of the metabolic syndrome and is strongl...

Introduction: Dysregulated glucocorticoid (GC) metabolism has been implicated in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). NAFLD extends from simple steatosis, to inflammation (steatohepatitis/NASH), fibrosis and consequent cirrhosis. It is often regarded as the hepatic manifestation of the metabolic syndrome and is independently associated with increased liver and cardiovascular mortality. Changes in GC metabolism have thus far been described in small num...